Table 3. Prevalence of antifungal drug resistance among bloodstream isolates of major Candida species/complexes tested during 2006–2011 and 2012 to 2017 in Kuwaita.
| Antifungal drug | Duration | Candida albicans | Candida parapsilosis | Candida orthopsilosis | Candida tropicalis | Candida glabrata | Candida krusei | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. tested | Resistant (%) | No. tested | Resistant (%) | No. tested | Resistant (%) | No. tested | Resistant (%) | No. tested | Resistant (%) | No. tested | Resistant (%) | ||
| Amphotericin B | 2006–2011 | 378 | 0 | 310 | 0 | 5 | 0 | 114 | 0 | 75 | 1 (1.4) | 15 | 1 (6.7) |
| 2012–2017 | 363 | 0 | 446 | 0 | 2 | 0 | 150 | 0 | 115 | 1 (1.1) | 16 | 0 | |
| Fluconazole | 2006–2011 | 371 | 3 (0.8) | 310 | 1 (0.3) | 5 | 0 | 112 | 1 (0.8) | 74 | 3 (4.1) | 13 | 0 |
| 2012–2017 | 363 | 5 (1.4) | 446 | 21 (4.7)b | 2 | 0 | 150 | 1 (0.7) | 115 | 14 (12.2) | 16 | 0 | |
| Voriconazole | 2006–2011 | 331 | 4 (1.2) | 274 | 0 | 5 | 0 | 108 | 1 (0.9) | 62 | 0 | 14 | 0 |
| 2012–2017 | 304 | 4 (1.3) | 360 | 7 (1.9)b | 1 | 0 | 117 | 0 | 84 | 0 | 12 | 0 | |
aBloodstream isolates of all Candida species tested in this study were susceptible to caspofungin and all isolates of C. dubliniensis were additionally susceptible to amphotericin B, fluconazole and voriconazole
bSignificantly higher rates of resistance to fluconazole and voriconazole observed for C. parapsilosis during 2012 to 2017 compared to 2006 to 2011 period are highlighted in boldface numbers